Nagler A, Slavin S, Yarkoni S, Fejgin M, Amiel A
Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.
Cancer Genet Cytogenet. 1994 Apr;73(2):130-3. doi: 10.1016/0165-4608(94)90196-1.
Detection of minimal residual disease is one of the major goals in bone marrow transplantation. We used a fluorescence in-situ hybridization technique to detect residual Philadelphia-chromosome positive cells in chronic myelogenous leukemia (CML) patients after sex-mismatch BMT. We analyzed the level of detection using probes for the BCR/ABL fusion product by comparison with results obtained with probes for the Y and X sex chromosomes. Detection of sex-mismatch chromosomes was significantly higher than that of the BCR/ABL translocation. In contrast, a higher specificity of residual tumor cell detection by the BCR/ABL probe was demonstrated because most of the sex-mismatch cells detected by FISH had a normal karyotype. Tumor-specific markers probes are thus superior and more accurate than sex-mismatch probes for detection of MRD in CML patients after BMT.
检测微小残留病是骨髓移植的主要目标之一。我们使用荧光原位杂交技术检测异基因骨髓移植后慢性粒细胞白血病（CML）患者残留的费城染色体阳性细胞。通过与Y和X性染色体探针的检测结果相比较，我们用BCR/ABL融合产物探针分析了检测水平。性染色体不匹配的检测率显著高于BCR/ABL易位的检测率。相比之下，由于荧光原位杂交检测到的大多数性染色体不匹配细胞具有正常核型，因此BCR/ABL探针检测残留肿瘤细胞具有更高的特异性。因此，在检测异基因骨髓移植后CML患者的微小残留病方面，肿瘤特异性标志物探针比性染色体不匹配探针更优越、更准确。
